GM Pharmaceuticals (შპს ჯი-ემ-პი)

panel 2026-09-21Ask

as filed · GEL, thousands

Line item	2017	2018	2019	2020	2021	2022	2023	2024	CAGR
Total Revenue	94,259	105,923	123,065	135,929	183,285	191,099	130,729	184,906	+10.1%
Total COGS	24,560	29,377	36,173	41,004	61,327	72,367	48,358	62,907	+14.4%
Gross Profit	69,699	76,545	86,892	94,926	121,958	118,732	82,371	122,000	+8.3%
Gross Margin	73.9%	72.3%	70.6%	69.8%	66.5%	62.1%	63.0%	66.0%
	32,646	42,867	53,368	51,206	54,879	53,738	61,045	59,937	+9.1%
EBITDA	37,053	33,678	33,524	43,719	67,079	64,994	21,326	62,063	+7.6%
EBITDA Margin	39.3%	31.8%	27.2%	32.2%	36.6%	34.0%	16.3%	33.6%
Total D&A	1,423	1,809	2,760	2,748	3,159	3,493	3,343	3,231	+12.4%
Impairment (non-financial)	0	0	0	3,251	6,624	4,591	9,350	4,455	+8.2%
EBIT / Operating Income	35,630	31,869	30,764	37,720	57,296	56,910	8,632	54,377	+6.2%
Total Interest Income	417	1,145	0	0	485	1,051	2,010	3,320	+34.5%
Total Interest Expense	638	103	449	456	272	243	285	145	-19.1%
	2,119	89	1,008	4,591	4,845	15,594	3,259	2,783	nmf
Profit Before Tax	33,289	33,000	31,323	41,855	52,664	42,124	7,098	60,335	+8.9%
Total Income Tax	0	0	316	805	1,107	3,891	0	0	+130.8%
Net Profit / (Loss)	12,560	29,491	27,515	39,419	50,872	37,046	5,724	59,308	+24.8%
Net Margin	13.3%	27.8%	22.4%	29.0%	27.8%	19.4%	4.4%	32.1%

GM Pharmaceuticals